Theras, Inc., D/b/a Bbot (bridgebio Oncology Therapeutics)
Clinical trials sponsored by Theras, Inc., D/b/a Bbot (bridgebio Oncology Therapeutics), explained in plain language.
-
New hope for KRAS lung cancer: first human trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called BBO-8520 in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The main goals are to check the drug's safety and see if it can shrink tumors. About 350 adults will take part, and the drug …
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 26, 2026 06:52 UTC
-
New drug aims to break Cancer's growth signals
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-10203 in about 392 adults with advanced solid tumors (like breast, lung, or colorectal cancer) that have not responded to other treatments. The drug works by blocking a key cancer growth pathway. The main goals are to find the sa…
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 26, 2026 06:51 UTC
-
New drug targets Hard-to-Treat KRAS cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in people with advanced solid tumors (lung, pancreatic, colorectal, or others) that have a specific KRAS gene mutation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Abo…
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 20, 2026 11:58 UTC